ملکہ شراوت ترنگے کی لپٹ میں آ گئی .. ویڈیو دیکھیں

Health care finds itself in the spotlight again this election cycle. Candidates on both sides of the aisle have made it a wedge issue, with the Democrats touting the expansion of coverage through the Affordable Care Act (ACA/Obamacare) as a big win and Republicans countering that the law is invasive, a regulatory burden and a superfluous inflation driver. With no clear presidential frontrunner to date, the somewhat murky health care policy outlook has negatively impacted investor sentiment. As we head into the fall campaign, investors may be unlikely to embrace the sector until they receive clarity on three key issues: the future of the individual commercial insurance market, prescription drug prices and entitlement spending. Hanging in the Balance: Individual Market Reforms We currently have three main Presidential candidates (Clinton, Trump and Cruz) and three different agendas for reforming the individual market. This was the market most impacted by Obamacare and the one area most likely to be affected by future changes to the law. Hence, this is the market segment most likely to experience disruption due to clumsy or shortsighted policy changes. Any policy change could impact over 18 million lives, so new regulations can’t be taken lightly. Ted Cruz has told voters that he would repeal Obamacare, but has yet to propose a replacement plan. The lack of insight into a future plan would create uncertainty for investors. Although Donald Trump has discussed “repealing and replacing” the ACA, his plan only reforms the individual market slightly and we don’t see his vision as a game changer. On the flip side, Hillary Clinton is an outspoken supporter of Obamacare and has suggested that she would only tweak the program to strengthen it. The Wildcard: Pharmaceutical Drug Pricing Regulation Current law prohibits the federal government from interfering in private sector negotiations, including negotiating drug prices in the Medicare benefit. There are also no direct price negotiations in Medicaid, although manufacturers have to adhere to a set pricing formula to participate in the program. Investors want to know if Congress is willing to revisit the Medicare Part D law. While Clinton and Trump have expressed an interest in direct negotiations with manufacturers, it remains unclear how the next administration would implement a new program. To improve pricing, the government would likely have to threaten to deny manufacturers the ability to sell their product to seniors. While the concept of a national formulary doesn’t sound too daunting, in reality it would be a political nightmare, triggering endless debates regarding which drugs should and should not be covered. At the end of the day, we would expect Congress to back off this idea and embrace more subtle changes, such as the recent reforms proposed by the Administration.

DOwnload And Watch Video From Here